PAD-mediated citrullination is a novel candidate diagnostic marker and druggable target for HPV-associated cervical cancer.

BB-cl-Amidine cervical cancer citrullination human papillomaviruses peptidylarginine deiminases

Journal

Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359

Informations de publication

Date de publication:
2024
Historique:
received: 21 12 2023
accepted: 27 02 2024
medline: 26 3 2024
pubmed: 26 3 2024
entrez: 26 3 2024
Statut: epublish

Résumé

Citrullination is an emerging post-translational modification catalyzed by peptidyl-arginine deiminases (PADs) that convert peptidyl-arginine into peptidyl-citrulline. In humans, the PAD family consists of five isozymes (PADs 1-4, 6) involved in multiple diseases, including cancer. Given that high-risk (hr) human papillomaviruses (HPVs) are the etiological agents of cervical cancer, in this study, we sought to determine whether PAD-mediated protein citrullination would play a functional role in the HPV-driven transformation of epithelial cells. Here we show that both total protein citrullination and PAD4 expression levels are significantly associated with cervical cancer progression. Specifically, epithelial immunostaining for PAD4 revealed an increasingly higher histoscore from low-grade (CIN1) to high-grade (CIN2, CIN3) cervical intraepithelial neoplasia, and invasive squamous cell carcinoma (SCC) lesions, raising the attractive possibility that PAD4 may be used as tumor staging markers. Furthermore, taking advantage of the epidermoid cervical cancer cell line CaSki, which harbors multiple copies of the integrated HPV16 genome, we show that the expression of E6 and E7 HPV oncoproteins is impaired by treatment with the pharmacological pan-PAD inhibitor BB-Cl-amidine. Consistently, p53 and p21, two targets of HPV oncoproteins, are upregulated by the PAD inhibitor, which undergoes cell growth arrest and apoptosis. Altogether, these findings highlight a novel mechanism by which hrHPVs alter host regulatory pathways involved in cell cycle and survival to gain viral fitness, raising the possibility that PADs may represent an attractive target for developing novel host-targeting antivirals effective in preventing cervical cancer progression.

Identifiants

pubmed: 38529474
doi: 10.3389/fcimb.2024.1359367
pmc: PMC10961408
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1359367

Informations de copyright

Copyright © 2024 Albano, Biolatti, Mazibrada, Pasquero, Gugliesi, Lo Cigno, Calati, Bajetto, Riva, Griffante, Landolfo, Gariglio, De Andrea and Dell’Oste.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Camilla Albano (C)

Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy.

Matteo Biolatti (M)

Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy.

Jasenka Mazibrada (J)

Department of Cellular Pathology, The Cotman Centre Norfolk and Norwich University Hospital, Norwich, United Kingdom.

Selina Pasquero (S)

Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy.

Francesca Gugliesi (F)

Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy.

Irene Lo Cigno (I)

Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.

Federica Calati (F)

Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.

Greta Bajetto (G)

Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy.
Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
Center for Translational Research on Autoimmune and Allergic Disease-CAAD, Novara, Italy.

Giuseppe Riva (G)

Department of Surgical Sciences, University of Turin, Turin, Italy.

Gloria Griffante (G)

IIGM Foundation - Italian Institute for Genomic Medicine, Turin, Italy.
Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.

Santo Landolfo (S)

Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy.

Marisa Gariglio (M)

Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.

Marco De Andrea (M)

Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy.
Center for Translational Research on Autoimmune and Allergic Disease-CAAD, Novara, Italy.

Valentina Dell'Oste (V)

Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy.

Classifications MeSH